Nigel Brooks
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.
Journal: Science advances
Published: May 15, 2026
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Journal: Oncogene
Published: June 24, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Journal: Cancer cell
Published: July 08, 2022
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis.
Journal: Nature communications
Published: November 21, 2020
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Journal: Cancer discovery
Published: May 27, 2020
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Journal: Immunity
Published: February 06, 2019
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026